Skip to main content

Our unique collection of technologies/capabilities places us at the forefront of heart failure with preserved ejection fraction (HFpEF) research. Using these strategies, our aims are as follows:

  1. Determine key mechanistic underpinnings in each subclass of HFpEF
  2. Develop novel management strategies and treatment guidelines to treat each HFpEF subclass (with Dr Sean Lal, co-Director of HFpEF clinic and Director of Sydney Heart Bank)
  3. Develop novel therapeutics to improve HFpEF outcome (with Dr Xuyu Liu, HRI).
  4. Employ novel techniques in human heart tissue to uncover novel mechanisms and test new treatments (with Prof Paul Bannon, Royal Prince Alfred Hospital and The Baird Institute).

Outcomes: New management guidelines and therapeutic agents for HFpEF, the most common form of heart failure globally that currently has no approved pharmacotherapies.